These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

368 related items for PubMed ID: 20596295

  • 21. Prepuberal intranasal dopamine treatment in an animal model of ADHD ameliorates deficient spatial attention, working memory, amino acid transmitters and synaptic markers in prefrontal cortex, ventral and dorsal striatum.
    Ruocco LA, Treno C, Gironi Carnevale UA, Arra C, Mattern C, Huston JP, de Souza Silva MA, Nikolaus S, Scorziello A, Nieddu M, Boatto G, Illiano P, Pagano C, Tino A, Sadile AG.
    Amino Acids; 2014 Sep; 46(9):2105-22. PubMed ID: 24862315
    [Abstract] [Full Text] [Related]

  • 22. Novel pharmacological targets for GABAergic dysfunction in ADHD.
    Ferranti AS, Luessen DJ, Niswender CM.
    Neuropharmacology; 2024 May 15; 249():109897. PubMed ID: 38462041
    [Abstract] [Full Text] [Related]

  • 23. Selective activation of Dopamine D3 receptors and norepinephrine transporter blockade enhances sustained attention.
    Marshall CA, Brodnik ZD, Mortensen OV, Reith MEA, Shumsky JS, Waterhouse BD, España RA, Kortagere S.
    Neuropharmacology; 2019 Apr 15; 148():178-188. PubMed ID: 30633928
    [Abstract] [Full Text] [Related]

  • 24. Attention-deficit/hyperactivity disorder: a selective overview.
    Biederman J.
    Biol Psychiatry; 2005 Jun 01; 57(11):1215-20. PubMed ID: 15949990
    [Abstract] [Full Text] [Related]

  • 25. Common prefrontal cortical gene expression profiles between adolescent SHR/NCrl and WKY/NCrl rats which showed inattention behavior.
    Dela Peña I, Bang M, Lee J, de la Peña JB, Kim BN, Han DH, Noh M, Shin CY, Cheong JH.
    Behav Brain Res; 2015 Sep 15; 291():268-276. PubMed ID: 26048425
    [Abstract] [Full Text] [Related]

  • 26. [Towards an understanding of the molecular mechanisms underlying the pharmacological treatments of attention deficit hyperactivity disorder].
    Castellanos FX, Acosta MT.
    Rev Neurol; 2011 Mar 01; 52 Suppl 1():S155-60. PubMed ID: 21365598
    [Abstract] [Full Text] [Related]

  • 27. Transcriptional profiling of SHR/NCrl prefrontal cortex shows hyperactivity-associated genes responsive to amphetamine challenge.
    Dela Peña IJI, Dela Peña I, de la Peña JB, Kim HJ, Sohn A, Shin CY, Han DH, Kim BN, Ryu JH, Cheong JH.
    Genes Brain Behav; 2017 Sep 01; 16(7):664-674. PubMed ID: 28422445
    [Abstract] [Full Text] [Related]

  • 28. Involvement of norepinephrine in the control of activity and attentive processes in animal models of attention deficit hyperactivity disorder.
    Viggiano D, Ruocco LA, Arcieri S, Sadile AG.
    Neural Plast; 2004 Sep 01; 11(1-2):133-49. PubMed ID: 15303310
    [Abstract] [Full Text] [Related]

  • 29. A review of the pathophysiology, etiology, and treatment of attention-deficit hyperactivity disorder (ADHD).
    Sharma A, Couture J.
    Ann Pharmacother; 2014 Feb 01; 48(2):209-25. PubMed ID: 24259638
    [Abstract] [Full Text] [Related]

  • 30. In vivo electrophysiological effects of methylphenidate in the prefrontal cortex: involvement of dopamine D1 and alpha 2 adrenergic receptors.
    Gronier B.
    Eur Neuropsychopharmacol; 2011 Feb 01; 21(2):192-204. PubMed ID: 21146374
    [Abstract] [Full Text] [Related]

  • 31. [Neurobiology of attention deficit/hyperactivity disorder].
    Purper-Ouakil D, Lepagnol-Bestel AM, Grosbellet E, Gorwood P, Simonneau M.
    Med Sci (Paris); 2010 May 01; 26(5):487-96. PubMed ID: 20510147
    [Abstract] [Full Text] [Related]

  • 32. Current concepts on the neurobiology of Attention-Deficit/Hyperactivity Disorder.
    Biederman J, Faraone SV.
    J Atten Disord; 2002 May 01; 6 Suppl 1():S7-16. PubMed ID: 12685515
    [Abstract] [Full Text] [Related]

  • 33. Catecholamine modulation of prefrontal cortical cognitive function.
    Arnsten AF.
    Trends Cogn Sci; 1998 Nov 01; 2(11):436-47. PubMed ID: 21227275
    [Abstract] [Full Text] [Related]

  • 34. Effects of methylphenidate on the catecholaminergic system in attention-deficit/hyperactivity disorder.
    Wilens TE.
    J Clin Psychopharmacol; 2008 Jun 01; 28(3 Suppl 2):S46-53. PubMed ID: 18480677
    [Abstract] [Full Text] [Related]

  • 35. Oral Administration of Methylphenidate (Ritalin) Affects Dopamine Release Differentially Between the Prefrontal Cortex and Striatum: A Microdialysis Study in the Monkey.
    Kodama T, Kojima T, Honda Y, Hosokawa T, Tsutsui KI, Watanabe M.
    J Neurosci; 2017 Mar 01; 37(9):2387-2394. PubMed ID: 28154152
    [Abstract] [Full Text] [Related]

  • 36. Orbitofrontal Signaling of Future Reward is Associated with Hyperactivity in Attention-Deficit/Hyperactivity Disorder.
    Tegelbeckers J, Kanowski M, Krauel K, Haynes JD, Breitling C, Flechtner HH, Kahnt T.
    J Neurosci; 2018 Jul 25; 38(30):6779-6786. PubMed ID: 29954849
    [Abstract] [Full Text] [Related]

  • 37. Catecholamine regulation of the prefrontal cortex.
    Arnsten AF.
    J Psychopharmacol; 1997 Jul 25; 11(2):151-62. PubMed ID: 9208378
    [Abstract] [Full Text] [Related]

  • 38. Adenosinergic system and nucleoside transporters in attention deficit hyperactivity disorder: Current findings.
    Valladão SC, França AP, Pandolfo P, Dos Santos-Rodrigues A.
    Neurosci Biobehav Rev; 2024 Sep 25; 164():105771. PubMed ID: 38880409
    [Abstract] [Full Text] [Related]

  • 39. Dopaminergic and noradrenergic contributions to functionality in ADHD: the role of methylphenidate.
    Engert V, Pruessner JC.
    Curr Neuropharmacol; 2008 Dec 25; 6(4):322-8. PubMed ID: 19587853
    [Abstract] [Full Text] [Related]

  • 40. Animal models of attention-deficit hyperactivity disorder.
    Russell VA, Sagvolden T, Johansen EB.
    Behav Brain Funct; 2005 Jul 15; 1():9. PubMed ID: 16022733
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 19.